๐ฐ Beigene News
Page 18 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
April 27, 2022
RATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC) 1
April 27, 2022
Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the
April 25, 2022
Equities analysts predict that BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) will report sales of $251.05 million for the current quarter, according to Zacks. Two analysts have provided estimates for BeiGene’s earnings. The highest sales estimate is $287.60 million and the lowest is $214.50 million. BeiGene reported sales of $605.87 million during the same quarter last […]
April 25, 2022
Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have been given a consensus recommendation of “Hold” by the eight ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the […]
April 22, 2022
Merck's former China head will returnย to the Big Pharmaย to lead international human health operations after a short stint at a Chinese company.
April 21, 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support
April 20, 2022
BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
April 15, 2022
BASEL (dpa-AFX) - BeiGene, Ltd. (BGNE) announced the China National Medical Products Administration or NMPA has granted approval to the company's anti-PD-1 antibody, tislelizumab, as a treatment
April 15, 2022
Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative
April 11, 2022
11.04.2022 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from the Phase 3 ALPINE trial showing BTK inhibitor BRUKINSA ... Seite 1